Specificity of adoptive chemoimmunotherapy of established syngeneic tumors - PubMed (original) (raw)
- PMID: 6156213
Specificity of adoptive chemoimmunotherapy of established syngeneic tumors
M A Cheever et al. J Immunol. 1980 Aug.
Abstract
To examine the specificity of adoptive chemoimmunotherapy (ACIT) of established syngeneic tumors, two noncross-reactive C57BL/6 tumors were studied: a Friend virus-induced tumor (FBL-3) and a chemically induced virus-negative tumor EL-4(G-). In vitro studies confirmed that these tumors are antigenically distinct by demonstrating that the cytotoxic responses of spleen cells from mice immunized in vivo and reexposed to tumor in vitro are immunologically specific. Studies of ACIT with cells from mice immunized in vivo demonstrated similar specificity. Mice receiving 5 x 10(6) FBL-3 on day 0 all died by day 13. Treatment on day 5 with cyclophosphamide (CY), 180 mg/kg, prolonged the median survival time (MST) to day 23. Treatment on day 5 with CY plus 2 x 10(7) normal nonimmune C57BL/6 cells or CY plus cells sensitized to EL-4(G-) had no additional effect on survival whereas 2 x 10(7) C57BL/6 cells sensitized to FBL-3 in vivo prolonged MST to day 64 and cured 13 of 32 mice. Similarly, mice given 2 x 10(5) EL-4(G-) on day 0 all died by day 16, and CY on day 5 prolonged the MST to day 22. As an adjunct to CY, 2 X 10(7) normal cells or cells sensitized to FBL-3 had a modest effect, prolonging the MST to days 37 and 36, respectively. However, treatment with CY plus 2 x 10(7) cells immune to EL-4(G-) cured 22 of 32 mice. The results demonstrate the immunologic specificity of ACIT of syngeneic tumors treated with immune syngeneic cells.
Similar articles
- Therapy of leukemia by nonimmune syngeneic spleen cells.
Cheever MA, Greenberg PD, Fefer A. Cheever MA, et al. J Immunol. 1980 May;124(5):2137-42. J Immunol. 1980. PMID: 7365249 - Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.
Berenson JR, Einstein AB Jr, Fefer A. Berenson JR, et al. J Immunol. 1975 Jul;115(1):234-8. J Immunol. 1975. PMID: 1080165 - Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro.
Cheever MA, Greenberg PD, Fefer A. Cheever MA, et al. Cancer Res. 1981 Jul;41(7):2658-63. Cancer Res. 1981. PMID: 7018668 - Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.
Eberlein TJ, Rosenstein M, Spiess PJ, Rosenberg SA. Eberlein TJ, et al. J Natl Cancer Inst. 1982 Jul;69(1):109-16. J Natl Cancer Inst. 1982. PMID: 6980314 - Specific adoptive immunotherapy: experimental basis and future potential.
Greenberg PD, Cheever MA, Fefer A. Greenberg PD, et al. Surv Immunol Res. 1982;1(1):85-90. doi: 10.1007/BF02918244. Surv Immunol Res. 1982. PMID: 6764836 Review. No abstract available.
Cited by
- Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.
Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, Barba P, Doglio M, Henderson D, Hudecek M, Kremer A, Markman J, Nauerth M, Negre H, Sanges C, Staber PB, Tanzi R, Delgado J, Busch DH, Kuball J, Luu M, Jäger U. Lickefett B, et al. Front Immunol. 2023 Dec 22;14:1303935. doi: 10.3389/fimmu.2023.1303935. eCollection 2023. Front Immunol. 2023. PMID: 38187393 Free PMC article. Review. - B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity.
Smith AS, Knochelmann HM, Wyatt MM, Rangel Rivera GO, Rivera-Reyes AM, Dwyer CJ, Ware MB, Cole AC, Neskey DM, Rubinstein MP, Liu B, Thaxton JE, Bartee E, Paulos CM. Smith AS, et al. J Immunother Cancer. 2022 Jan;10(1):e003078. doi: 10.1136/jitc-2021-003078. J Immunother Cancer. 2022. PMID: 35017148 Free PMC article. - Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma.
Flesner BK, Wood GW, Gayheart-Walsten P, Sonderegger FL, Henry CJ, Tate DJ, Bechtel SM, Donnelly LL, Johnson GC, Kim DY, Wahaus TA, Bryan JN, Reyes N. Flesner BK, et al. J Vet Intern Med. 2020 Sep;34(5):2056-2067. doi: 10.1111/jvim.15852. Epub 2020 Jul 10. J Vet Intern Med. 2020. PMID: 32649801 Free PMC article. - Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.
Suryadevara CM, Desai R, Farber SH, Choi BD, Swartz AM, Shen SH, Gedeon PC, Snyder DJ, Herndon JE 2nd, Healy P, Reap EA, Archer GE, Fecci PE, Sampson JH, Sanchez-Perez L. Suryadevara CM, et al. Clin Cancer Res. 2019 Jan 1;25(1):358-368. doi: 10.1158/1078-0432.CCR-18-1211. Epub 2018 Nov 13. Clin Cancer Res. 2019. PMID: 30425092 Free PMC article. - Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.
Santos JM, Cervera-Carrascon V, Havunen R, Zafar S, Siurala M, Sorsa S, Anttila M, Kanerva A, Hemminki A. Santos JM, et al. Mol Ther. 2018 Sep 5;26(9):2243-2254. doi: 10.1016/j.ymthe.2018.06.001. Epub 2018 Jul 13. Mol Ther. 2018. PMID: 30017877 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials